Edition:
United Kingdom

Juniper Pharmaceuticals Inc (JNP.OQ)

JNP.OQ on NASDAQ Stock Exchange Global Select Market

8.85USD
23 May 2018
Change (% chg)

$0.20 (+2.31%)
Prev Close
$8.65
Open
$8.70
Day's High
$8.95
Day's Low
$8.70
Volume
20,281
Avg. Vol
20,588
52-wk High
$13.10
52-wk Low
$4.05

Select another date:

Thu, May 10 2018

BRIEF-Juniper Pharmaceuticals Reports Q1 Earnings Per Share Of $0.06

* JUNIPER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform

* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM

BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience

* JUNIPER PHARMACEUTICALS LICENSES INTRAVAGINAL RING (IVR) PLATFORM TO DARÉ BIOSCIENCE

BRIEF-Juniper Pharmaceuticals Appoints Richard Messina To Board Of Directors

* JUNIPER PHARMACEUTICALS APPOINTS RICHARD MESSINA TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Juniper Pharmaceuticals Qtrly Basic EPS $0.11

* JUNIPER PHARMACEUTICALS REPORTS FULL-YEAR 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Juniper Pharmaceuticals To Explore Strategic Alternatives

* JUNIPER PHARMACEUTICALS - ‍ ENGAGED ROTHSCHILD AS ITS INDEPENDENT FINANCIAL ADVISOR TO ASSIST JUNIPER IN EVALUATING POTENTIAL STRATEGIC ALTERNATIVES​ Source text for Eikon: Further company coverage:

BRIEF-Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress

* JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS

Select another date: